Introduction
Management of chronic diseases with acute exacerbations, such as heart failure (HF), is often fragmented across primary and secondary care.
1 -4 Yet, most clinical trials and registries that have guided HF care and informed patients about their prognosis have had a HF-related hospitalization as a prerequisite for study enrolment. As a result, the extent to which this evidence should be extrapolated to HF patients seen in other levels of the healthcare system, those who are never hospitalized for example, remains largely uninvestigated. Therefore, as for many diseases, external validity of HF trials and cohorts is questionable and reflects the paucity in our understanding of how evidence should be generalized into guidelines. 5 The challenge to prognosticate heterogeneous diseases such as HF was recently reinforced by data from the Swedish healthcare system, showing that patients included in trials were poorly representative of patients with HF encountered in the general population, and approximately one in three such patients had never been hospitalized for HF. 6 Data from Sweden and other population-based studies from various countries are now increasingly available. 6 -8 However, to date, most studies that report on prognosis of HF produced survival estimates for HF in general, 9 -14 acute hospital admissions, 15 -19 or stratified for cardiac systolic dysfunction 20 -24 (i.e. reduced-, mid-, or preserved range of LVEF) for example. We hypothesize that prognostication of HF can merit from strata based on level of care to allow assessment of novel patient groups, such as patients known with HF in ambulatory care (i.e. primary or outpatient secondary care) who have not been hospitalized with HF for example, or vice versa.
Electronic health records (EHRs) are now used as an integral part of routine daily practice in primary, and, to a lesser extent, in secondary care in the UK. 25, 26 They provide an unprecedented amount of data available for research and, as a result, have gained increasing attention from the scientific community as well as governmental institutions. 27 Accordingly, we linked prospectively collected data from primary care, hospital admissions, and death certificates for 2.1 million inhabitants of England in the Cardiovascular disease research using Linked Bespoke studies and Electronic Health Records (CALIBER) programme. 28 This platform has been extensively validated for cardiovascular research. 29 -32 Our objectives were to assess the distribution and prognostic impact of HF among patients with HF recorded in primary care (including outpatient secondary care) (PC), acute hospital admissions, or both. For these respective strata, we assessed patient characteristics, their HF management, and their prognosis in terms of 90-day and 5-year mortality.
Methods

Study design and data sources
We used a cohort study design, based on the CALIBER programme, as described previously. 28 35 We used data from 2.13 million patients across 225 CPRD practices in England that consented to data linkage. 28 Previous work has shown that CPRD patients are representative of the general population of the UK in terms of sex, age, ethnicity, 35, 36 and overall mortality 37 , thereby validating CPRD for epidemiological research. 32 HES is a database containing dates and diagnostic codes for all elective and emergency admissions and procedures to National Health Service hospitals in England (www.hscic.gov.uk/hes). ONS is a database containing death certificates and provides date and causes of death (www.ons.gov.uk/ons).
Study population and definition of heart failure
We included all patients with incident HF from 1 January 1997 to 26 March 2010 (when all record sources were concurrent). The diagnosis of HF was based on Read codes for CPRD data and International Classification of Diseases (ICD)-9 or −10 codes in HES and ONS, using a phenotyping approach previously described (details on algorithms are available on www.caliberresearch.org/portal/ and Supplementary material online, Table S2 ). 38 We excluded patients under 30 years of age and those not registered during the study period at a CPRD practice, or whose CPRD practices did not submit data for at least 1 year before the diagnosis of HF. The study flow chart is shown in the Supplementary material online, Figure S1 . Based on the individual distribution of HF records, we formulated four groups of interest based on the presence or absence of a HF record in each of the three data sources (Supplementary material online, Figure S2 ).
Clinical details of heart failure
We sought additional clinical details in the PC record relevant to diagnosis and management, including LV dysfunction confirmed by cardiac imaging, an elevated BNP concentration, referral to HF care, referral to a cardiologist, the use of loop diuretics, and symptoms and signs suggestive of HF. Relevant codes to support these criteria are listed in Table S3 in the Supplementary material online.
Baseline characteristics
For each patient, information on demographics (i.e. age, sex, and social deprivation), cardiovascular risk factors (i.e. smoking, hypertension, diabetes, systolic blood pressure, and body mass index), blood tests (e.g. haemoglobin, creatinine, and BNP), co-existing morbidities (COPD, cancer, and depression), and drug prescription [loop diuretics, ACE inhibitors, ARBs, beta-blockers, and mineralocorticoid receptor antagonists (MRAs)] were all obtained from PC consultations recorded in CPRD. Risk factors and endpoints used in this study were previously defined and their phenotyping algorithms combining Read, ICD-10, drug, and procedure codes are published online and can be found at http://www.caliberresearch.org/portal/. 30, 39 Measured values such as blood pressure were based on the value closest to the first recorded diagnosis date. A patient was considered to be adherent to a medication if there was at least one prescription of the drug present within plus or minus 6 months of the HF diagnosis.
Statistical analyses
Hazard ratios (HRs) were derived from Cox models, with time since first HF diagnosis as the time scale, adjusted for baseline age (linear), and stratified by sex and GP practice, to take clustering between practices into account. Proportionality of hazard was verified by plotting the Schoenfeld residuals. We produced Kaplan-Meier cumulative incidence curves for 90-day and 5-year all-cause, cardiovascular, and HF-specific mortality for HF patients, stratified by EHR source (Supplementary material online, Figure S2 ). In Cox models of 5-year mortality, we used the age-and sex-matched general population as the reference group. We matched patients with HF recorded in one of their EHRs in a 1:1 ratio with an age-and sex-matched general population drawn from the 2.13 million study participants in CALIBER using the R package 'MatchIt' with caliper set at 0.15. Data were analysed using R version 3.1.2.
Ethical approval
This study was approved by the Independent Scientific Advisory Committee of the Medicines and Healthcare products Regulatory Agency (Protocol number 14_246R). The protocol was registered at clinicaltrial.gov (NCT02551016).
Results
Distribution of heart failure in the general population
Out of 2 134 615 patients in CALIBER, we identified 89 554 patients (4.2%) with a record of incident HF. The distribution of HF recorded in primary care, hospital admissions, or cause of death is shown in Figure 1 . Out of all HF patients, 26% were recorded in primary care only, 27% in both primary care and hospital admissions, 34% in hospital admissions only, and 13% had HF as cause of death without a previous record in primary care or hospital admissions ( Figure 1 ). Among patients with both HF recorded in primary care and hospital admissions, 38% were first recorded during hospitalization and the median time for an accompanying record of HF in PC was 29 days [interquartile range (IQR) 10-190 days] (Supplementary material online, Figure S3 ). Lastly, 32 338 out of 54 310 (59.5%) patients who were hospitalized for HF had a single HF-related hospitalization episode throughout follow-up (Supplementary material online, Figure S4 ) Lifestyle, cardiovascular risk factors, and co-morbidities (Table 1) . Overall, cardiovascular risk factors and co-morbidities were less common in patients with HF in PC who were never hospitalized, and the highest prevalence was observed in patients identified in HF-related hospital admissions alone or in combination with PC, as were modifiable lifestyle factors such as smoking ( Table S6 ).
Heart failure management
An ACE inhibitor or an ARB was prescribed in 13 138 out of 23 547 (55.8%) PC patients who were never hospitalized but only in 11 844 out of 30 629 (38.7%) patients hospitalized for HF without a PC record, compared with the highest prescription rate in 17 057 out of 23 681 (72.0%) of patients known in both levels of care ( Table 1 ). In addition, beta-blockers were only prescribed in 7179 (30.5%), 7985 (26.1%), and 8190 (34.6%) of patients for these three groups, respectively. The relatively newest evidence-based treatment of HF is the addition of an MRA, and these were Figure 2 shows the Kaplan-Meier curves for 90-day survival (Figure 2A-C population (whose hazard was set as the reference) ( Figure 3) . With regard to risk factors associated with poor outcome, multivariable Cox proportional hazard models showed that age, concomitant COPD, and diabetes were amongst the strongest predictors of death (Supplementary material online, 
Discussion
We assessed EHR data of >2 million people for the presence of HF, within its real-world context using three linked data sources:
primary care (CPRD), hospital admissions for HF (HES), and the mortality registry (ONS). Among nearly 90 000 patients identified with HF, a quarter of all HF is recorded in primary care and these patients are never hospitalized for HF-such patients are largely excluded from trials, registries, and other studies-yet still had a high 5-year mortality. Secondly, about a third of patients were given their first diagnosis of HF during an acute hospitalization but were not followed up after discharge in primary care. These patients had the worst 5-year survival, and the worst medical management. Taken together, these findings support the wider use of linked EHR sources to facilitate a more consistent approach to identification, profiling, and treatment of HF patients in the real world to improve adherence to evidence-based care and reduce mortality.
Heart failure in primary care without heart failure-related hospital admissions-the 26% Importantly, we found that in the UK, approximately a quarter of all patients with HF in the general population were seen in primary care-and presumingly also in the outpatient secondary care setting-but were never acutely hospitalized for the disease. This is roughly similar to that reported in the only other investigation of the distribution of HF across different care settings. 6 To our knowledge, this is the first study that assessed the prognostic burden of HF based on level of care. Here, we show that although acute hospitalizations for HF are well known for their negative impact on prognosis, 15, 16, 40 unexpectedly 5-year survival estimates were roughly comparable between primary care patients who had never been hospitalized for HF and those who had. As the natural course of HF commonly includes periods of destabilizations requiring a hospital admission, it is uncertain which factors other than HF hospital admissions are responsible for the low survival in these patients. Although under-recording of hospital admissions in HES cannot be ruled out, patients in this group could also reflect end-stage HF in which the decompensated patient was not referred . to the hospital as part of end-of-life counselling by the GP, or that these patients died because of competing risks.
Hospitalization for heart failure without a primary care record-the 34%
We found that ∼40% of all HF diagnoses in the general population were made as a result of an acute hospitalization. Importantly, our study shows (as has been described for other diseases, such as cancer 41 ) that de novo hospital admissions were strongly associated with mortality compared with diagnoses that are formulated in primary care or in a hospital outpatient setting. While it is possible that some of these cases may have been fulminant, with no opportunity for diagnosis in the community, it is likely that in many cases the diagnosis during an acute admission was late and already associated with high levels of disease severity.
Besides disease severity, it stands to reason that at least part of their poor prognosis could be explained by their medical management, being the worst of all three groups with the lowest coverage of ACE inhibitors or ARBs, beta-blockers, and MRAs (Table 1) . Hence, the lack of a primary care record in these patients might be the result of a quality of care gap between primary and secondary care. Indeed, the importance of improved transition between hospital and ambulant settings was recently reinforced by Al-Dumluji et al. showing that high quality discharge summaries were associated with a reduced number of readmissions.
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Heart failure diagnosis at deaththe 13%
With linkage to the national mortality register, this study advances previous reports from Sweden 6 or Germany 7 by quantifying HF-specific mortality. Notably, we found that 13% of 89 554 patients allegedly died of HF but were not recorded as having had HF prior to their death in primary care, nor were they admitted to the hospital for HF (Supplementary material online, Table Figure 3 Cox proportional hazard models for association between electronic health record record for heart failure (HF) and 5-year all-cause, cardiovascular, and HF-related mortality, stratified by HF recorded in primary care, acute HF hospital admissions, or both. CI, confidence interval; HR, hazard ratio.
S4).
Work to characterize these patients further showed that they were on average older, more frequently women, had higher levels of social deprivation, and showed fewer traditional cardiovascular risk factors. Although diagnosing HF as cause of death can be difficult, these findings suggest that there could be opportunities for improving screening, identification, and treatment of HF in these elderly patients, thereby potentially preventing HF-attributable deaths.
Limitations
The HF diagnoses used in this study were based on Read and/or ICD codes related to HF. In general, diagnoses recorded in CPRD or HES are sufficiently robust to permit their use for research purposes. 37, 43 However, one limitation concerns the inability to validate a diagnosis of HF directly using a gold standard (i.e. confirm HF cases by expert panel review of clinical notes and diagnostic tests) as CALIBER data are anonymized to safeguard patient privacy. As in previous studies, 30 
Clinical implications
Our findings have important clinical implications. First, the joint care in both primary and secondary care was associated with higher prescription rates of HF medication. This leaves two large groups of patients who could be potentially undertreated in current practice, being patients solely seen in ambulatory care (i.e. primary care and outpatient secondary care) and patients with a discharge diagnosis of HF in acute hospital admissions without a concurrent PC record. Higher levels of social deprivation in these two groups hint that certain HF patients are prone to suboptimal treatment in daily clinical care. Secondly, our findings underline the need for follow-up after a discharge diagnosis of HF that should include a pro-active diagnostic work-up with joint effort in both PC and outpatient secondary care. With increasing evidence from the real world generated from programmes such as CALIBER or the ARNO database by Maggioni and co-workers, 46 novel high-risk groups become apparent, and those described in this study are currently not reflected as high-risk individuals in US or European guidelines. 47, 48 Lastly, to date, almost all clinical trials have been enrolling patients with HF who have been hospitalized at least once. Here, we show that this choice impairs the generalizability towards a quarter of all HF patients in the general population who are never hospitalized. To increase external validity, we propose that future trials follow the BNP inclusion criterion as used in the PARADIGM-HF trial involving sacubitril/valsartan, rather than include trial participants based on an acute HF-related hospital admission. 49, 50 
Conclusions
In the general population, one in four patients with newly diagnosed HF will not be hospitalized for HF within a median follow-up of 1.7 years, yet they still have a dismal 5-year prognosis. Patients admitted to hospital with HF but not known with HF in primary care have the worst management and survival. Mitigating the prognostic burden of HF requires greater consistency across primary and secondary care in the identification, profiling, and treatment of patients. 
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